NasdaqCM:EXASBiotechs
Does Oncoguard Liver’s Strong Data Transform the Growth Narrative for Exact Sciences (EXAS)?
Earlier this month, Exact Sciences reported strong third quarter results, raised its full-year revenue outlook, and announced pivotal clinical validation data showing its Oncoguard Liver blood test outperformed ultrasound in detecting early-stage hepatocellular carcinoma.
These developments underscore the company's expanding leadership in cancer diagnostics, particularly as it enhances its portfolio with innovative blood-based tests and exclusive U.S. rights to Freenome's colorectal cancer...